本帖最后由 老马 于 2012-1-13 21:20 编辑
" A3 S3 M ? |6 ]& w: T- E3 O1 F
8 Z+ A: [4 @! q$ s' O爱必妥和阿瓦斯丁的比较
7 y- B/ V0 S$ n6 n# f0 Y
A1 c1 X4 r; F7 l* I* O) `
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
' r! W1 l3 I+ o
- D3 x7 g1 Q0 p
) K* k$ B$ j- |; [# q* N
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
6 Z: a: q4 B9 g( J: J' ?9 {==================================================
; x. Z) U( Y4 EOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
7 c$ C- ]# \5 o' h! |% Y8 NPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
6 N; W4 |) E; H- Z/ nResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.) P8 ?- ^( n/ E7 q" t+ |
|